Name | Number of supported studies | Average coverage | |
---|---|---|---|
Mueller cell | 6 studies | 28% ± 7% | |
cardiac muscle cell | 5 studies | 32% ± 9% | |
oligodendrocyte precursor cell | 5 studies | 31% ± 11% |
Insufficient scRNA-seq data for expression of VIPR2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 98% | 737.16 | 239 / 245 | 78% | 2.76 | 390 / 502 |
brain | 46% | 92.16 | 1212 / 2642 | 85% | 27.35 | 600 / 705 |
ovary | 100% | 1051.43 | 180 / 180 | 30% | 0.85 | 130 / 430 |
pancreas | 100% | 1016.29 | 328 / 328 | 29% | 0.63 | 52 / 178 |
uterus | 98% | 700.24 | 166 / 170 | 24% | 0.86 | 111 / 459 |
breast | 78% | 267.56 | 359 / 459 | 35% | 2.50 | 396 / 1118 |
stomach | 82% | 639.13 | 296 / 359 | 23% | 0.79 | 65 / 286 |
blood vessel | 99% | 831.73 | 1317 / 1335 | 0% | 0 | 0 / 0 |
heart | 98% | 673.69 | 846 / 861 | 0% | 0 | 0 / 0 |
intestine | 87% | 739.88 | 838 / 966 | 11% | 0.26 | 59 / 527 |
bladder | 90% | 580.90 | 19 / 21 | 6% | 0.13 | 32 / 504 |
esophagus | 68% | 621.60 | 985 / 1445 | 8% | 0.16 | 15 / 183 |
muscle | 71% | 235.69 | 570 / 803 | 0% | 0 | 0 / 0 |
adipose | 66% | 536.58 | 790 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 51% | 1.16 | 41 / 80 |
kidney | 31% | 59.01 | 28 / 89 | 6% | 0.21 | 50 / 901 |
lung | 14% | 31.47 | 82 / 578 | 15% | 0.48 | 170 / 1155 |
adrenal gland | 5% | 8.16 | 13 / 258 | 15% | 0.94 | 34 / 230 |
skin | 13% | 23.09 | 235 / 1809 | 6% | 0.13 | 29 / 472 |
thymus | 3% | 5.58 | 18 / 653 | 13% | 2.17 | 81 / 605 |
spleen | 10% | 20.00 | 24 / 241 | 0% | 0 | 0 / 0 |
peripheral blood | 4% | 7.40 | 37 / 929 | 0% | 0 | 0 / 0 |
liver | 1% | 0.98 | 2 / 226 | 2% | 0.13 | 9 / 406 |
tonsil | 0% | 0 | 0 / 0 | 2% | 0.08 | 1 / 45 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0007165 | Biological process | signal transduction |
GO_0007188 | Biological process | adenylate cyclase-modulating G protein-coupled receptor signaling pathway |
GO_0048662 | Biological process | negative regulation of smooth muscle cell proliferation |
GO_0007267 | Biological process | cell-cell signaling |
GO_0007166 | Biological process | cell surface receptor signaling pathway |
GO_0005886 | Cellular component | plasma membrane |
GO_0008528 | Molecular function | G protein-coupled peptide receptor activity |
GO_0017046 | Molecular function | peptide hormone binding |
GO_0004930 | Molecular function | G protein-coupled receptor activity |
GO_0004999 | Molecular function | vasoactive intestinal polypeptide receptor activity |
Gene name | VIPR2 |
Protein name | Vasoactive intestinal peptide receptor 2 isoform B Vasoactive intestinal peptide receptor 2 Vasoactive intestinal peptide receptor 2 isoform A Vasoactive intestinal peptide receptor 2 isoform C Vasoactive intestinal polypeptide receptor 2 (VIP-R-2) (Helodermin-preferring VIP receptor) (Pituitary adenylate cyclase-activating polypeptide type III receptor) (PACAP type III receptor) (PACAP-R-3) (PACAP-R3) (VPAC2) |
Synonyms | VIP2R |
Description | FUNCTION: This is a receptor for VIP as well as PACAP-38 and -27, the activity of this receptor is mediated by G proteins which activate adenylyl cyclase. Can be coupled to phospholipase C. . |
Accessions | ENST00000421760.2 X5D7R3 ENST00000262178.7 [P41587-1] ENST00000377633.7 [P41587-2] E9PCR5 P41587 ENST00000402066.5 X5D7Q6 X5DP12 C9JCP7 |